Clinical Trials Logo

Hereditary Spastic Paraparesis clinical trials

View clinical trials related to Hereditary Spastic Paraparesis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04768166 Completed - Clinical trials for Hereditary Spastic Paraparesis

Testing Miglustat Administration in Subjects With Spastic Paraplegia 11

TreatSPG11
Start date: June 15, 2021
Phase: Phase 2
Study type: Interventional

Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that produces spatacsin, a protein involved in lysosomal function. Studies performed in skin cells (fibroblasts) from SPG11 patients, mice and zebrafish models of the disease showed that the material accumulated in the lysosomes is made of glycosphingolipids (GSL). Miglustat is a drug that inhibits an enzyme called glucosylceramide synthetase (GCS) which is used for the production of GSL. Miglustat, therefore, helps to delay the production of GSL. This study aims to collect preliminary data on the safety of miglustat on the SPG11 disease and to assess biomarkers.

NCT ID: NCT04256681 Completed - Clinical trials for Hereditary Spastic Paraparesis

SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)

Start date: October 30, 2018
Phase: N/A
Study type: Interventional

The Self-Notion and Perception (SNAP) questionnaire developed at IRCCS E.Medea by Eleonora Diella and Roberta Morganti, arises from the need to quantify the subjective perception of the patient suffering from HSP of the typical symptoms of pathology, such as spasticity, weakness, changes in balance, resistance in walking, pain and fatigue. The purpose of this study is to validate this instrument and test its reliability, looking for correlations with the measurement scales used in the literature for the evaluation of the patient with HSP. The most used for this population are the Spastic Paraplegia Rating Scale (SPRS) and the Six-Minute Walk Test (6MWT) which assess the severity of the disease and the level of endurance (8-9) respectively.

NCT ID: NCT00677768 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

BIO_ALS-01
Start date: April 2008
Phase: N/A
Study type: Observational

The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression. Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.